187 related articles for article (PubMed ID: 33860729)
1. Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer.
Kuehl PJ; Yingling CM; Dubose D; Burke M; Revelli DA; Chen W; Dye WW; Belinsky SA; Tessema M
Drug Deliv; 2021 Dec; 28(1):767-775. PubMed ID: 33860729
[TBL] [Abstract][Full Text] [Related]
2. Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model.
Kuehl PJ; Grimes MJ; Dubose D; Burke M; Revelli DA; Gigliotti AP; Belinsky SA; Tessema M
Drug Deliv; 2018 Nov; 25(1):1127-1136. PubMed ID: 29779406
[TBL] [Abstract][Full Text] [Related]
3. Improved Therapeutic Efficacy of Topotecan Against A549 Lung Cancer Cells with Folate-targeted Topotecan Liposomes.
Zhang J; Shi W; Xue G; Ma Q; Cui H; Zhang L
Curr Drug Metab; 2020; 21(11):902-909. PubMed ID: 32851958
[TBL] [Abstract][Full Text] [Related]
4. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
5. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
Kummar S; Chen A; Ji J; Zhang Y; Reid JM; Ames M; Jia L; Weil M; Speranza G; Murgo AJ; Kinders R; Wang L; Parchment RE; Carter J; Stotler H; Rubinstein L; Hollingshead M; Melillo G; Pommier Y; Bonner W; Tomaszewski JE; Doroshow JH
Cancer Res; 2011 Sep; 71(17):5626-34. PubMed ID: 21795476
[TBL] [Abstract][Full Text] [Related]
7. Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.
Bączek T; Konieczna L; Belka M; Maciejka-Kapuścińska L; Wiśniewski J; Niedźwiecki M; Balcerska A; Adamkiewicz-Drożyńska E; Wachowiak J
J Pharm Biomed Anal; 2012 Nov; 70():330-6. PubMed ID: 22658903
[TBL] [Abstract][Full Text] [Related]
8. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
[TBL] [Abstract][Full Text] [Related]
9. Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
Dowlati A; Levitan N; Gordon NH; Hoppel CL; Gosky DM; Remick SC; Ingalls ST; Berger SJ; Berger NA
Cancer Chemother Pharmacol; 2001; 47(2):141-8. PubMed ID: 11269740
[TBL] [Abstract][Full Text] [Related]
10. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
11. 5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming.
Kuehl PJ; Tellez CS; Grimes MJ; March TH; Tessema M; Revelli DA; Mallis LM; Dye WW; Sniegowski T; Badenoch A; Burke M; Dubose D; Vodak DT; Picchi MA; Belinsky SA
Br J Cancer; 2020 Apr; 122(8):1194-1204. PubMed ID: 32103148
[TBL] [Abstract][Full Text] [Related]
12. New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.
Huang CH; Treat J
Oncology; 2001; 61 Suppl 1():14-24. PubMed ID: 11598410
[TBL] [Abstract][Full Text] [Related]
13. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
[TBL] [Abstract][Full Text] [Related]
14. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.
Tsunetoh S; Terai Y; Sasaki H; Tanabe A; Tanaka Y; Sekijima T; Fujioka S; Kawaguchi H; Kanemura M; Yamashita Y; Ohmichi M
Cancer Biol Ther; 2010 Dec; 10(11):1137-46. PubMed ID: 20935474
[TBL] [Abstract][Full Text] [Related]
15. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB
Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060
[TBL] [Abstract][Full Text] [Related]
16. Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience.
Grahn AY; Bankiewicz KS; Dugich-Djordjevic M; Bringas JR; Hadaczek P; Johnson GA; Eastman S; Luz M
J Neurooncol; 2009 Nov; 95(2):185-197. PubMed ID: 19466380
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Bruzzese F; Rocco M; Castelli S; Di Gennaro E; Desideri A; Budillon A
Mol Cancer Ther; 2009 Nov; 8(11):3075-87. PubMed ID: 19887547
[TBL] [Abstract][Full Text] [Related]
18. Therapy of small cell lung cancer with emphasis on oral topotecan.
Pirker R; Berzinec P; Brincat S; Kasan P; Ostoros G; Pesek M; Plāte S; Purkalne G; Rooneem R; Skricková J; Stanculeanu D; Timcheva C; Tzekova V; Zakotnik B; Zielinski CC; Zwitter M
Lung Cancer; 2010 Oct; 70(1):7-13. PubMed ID: 20576312
[TBL] [Abstract][Full Text] [Related]
19. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer.
Jain A; Jain SK
Drug Dev Ind Pharm; 2016 Jan; 42(1):136-149. PubMed ID: 26006330
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
